Practice of HER-2 immunohistochemistry in breast carcinoma in Austria

Pathology and Oncology Research

Volumn 14, Issue 3, 2008, Pages 253-259

  Reiner Concin, A ^a,g   Regitnig, P ^b   Dinges, H P ^c   Hofler G ^b   Lax, S ^a   Muller Holzner E ^d   Obrist, P ^e   Rudas, M ^f  

^a Donauspital ^*  (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c GENERAL HOSPITAL KLAGENFURT   (Austria)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e Pathohistological Laboratory   (Austria)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

^g Pathologie Bakteriol Institut   (Austria)

Author keywords

Breast cancer; HER 2; Immunohistochemistry; Quality assurance; Reproducibility

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; AUSTRIA; BREAST CARCINOGENESIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LABORATORY DIAGNOSIS; SENSITIVITY AND SPECIFICITY;

AUSTRIA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; QUALITY ASSURANCE, HEALTH CARE; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 58549109409     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-008-9079-z     Document Type: Article

References (22)

1. AC Wolff ME Hammond JN Schwartz 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 18 43
2. A Gennari MP Sormani P Pronzato 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 14 20
3. H Yamauchi V Stearns DF Hayes 2001 When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer J Clin Oncol 19 2334 2356
4. G Konecny G Pauletti M Pegram 2003 Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer J Natl Cancer Inst 95 142 153
5. S Ménard P Valagussa S Pilotti 2001 Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables J Clin Oncol 19 329 335
6. MF Press G Hung W Godolphin 1994 Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression Cancer Res 54 2771 2777
7. S Wang MH Saboorian EP Frenkel 2001 Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard Am J Clin Pathol 116 495 503
8. Italian Network for Quality Assurance of Tumor Biomarkers (INQAT) Group; SIAPEC-IAP 2005 Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer: an update from INQAT round III Int J Biol Markers 20 189 194
9. S Paik J Bryant E Tan-Chiu 2002 Real-world performance of HER2 testing-National Surgical Adjuvant Breast and Bowel Project experience J Natl Cancer Inst 94 852 854
10. A Rhodes B Jasani E Anderson 2002 Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries Am J Clin Pathol 118 408 417
11. Fleiss JG (1981) Statistical methods for rates and proportions. Wiley, New York, NY, pp 225-232
12. JR Landis GG Koch 1977 The measurement of observer agreement for categorical data Biometrics 33 159 174
13. M Bilous M Dowsett W Hanna 2003 Current perspectives on HER2 testing: a review of national testing guidelines Mod Pathol 16 173 182
14. IO Ellis J Bartlett M Dowsett 2004 Best Practice No 176: Updated recommendations for HER2 testing in the UK J Clin Pathol 57 233 237
15. P Bertheau D Cazals-Hatem V Meignin 1998 Variability of immunohistochemical reactivity on stored paraffin slides J Clin Pathol 51 370 374
16. A Rhodes D Borthwick R Sykes 2004 The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab Am J Clin Pathol 122 51 60
17. TW Jacobs AM Gown H Yaziji 1999 Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer J Clin Oncol 17 1974 1982
18. A Lebeau D Deimling C Kaltz 2001 Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization J Clin Oncol 19 354 63
19. RR Tubbs JD Pettay PC Roche 2001 Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message J Clin Oncol 19 2714 2721
20. MP Hoang AA Sahin NG Ordòñez 2000 HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma Am J Clin Pathol 113 852 859
21. TA Thomson MM Hayes JJ Spinelli 2001 HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization Mod Pathol 14 1079 1086
22. M Dietel IO Ellis H Höfler 2007 Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists Virchows Arch 51 19 25